In summary, whereas CD19 CAR T arguably has a complementary role in bridging to allo-HCT in the B-ALL algorithm, it may supplant allo-HCT in most patients with relapsed NHL based on favorable toxicity and at least comparable efficacy. Here, CD19 is linked to non-Hodgkin lymphoma.